Cargando…
Cost of a lymphedema treatment mandate - 16 years of experience in the Commonwealth of Virginia
BACKGROUND: Treatment of chronic illness accounts for over 90% of Medicare spending. Chronic lymphedema places 3–10 million Americans at risk for recurrent cellulitis. Without convincing predictions of the costs and benefits of lymphedema treatment, insurers are reluctant to fully cover treatment of...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308910/ https://www.ncbi.nlm.nih.gov/pubmed/35870018 http://dx.doi.org/10.1186/s13561-022-00388-6 |